Scientists find that removing IGF2BP3 selectively targets cancer cells while leaving healthy cells alone
UCLA Broad Stem Cell Research Center
Dr. Dinesh Rao and his colleagues had previously identified the IGF2BP3 protein as a factor in driving the development of leukemia through its regulation of RNA messages. Denise Heady |
July 28, 2021
Removing a protein that is often overexpressed in a rare and aggressive subtype of leukemia can help to slow the cancer’s development and significantly increase the likelihood of survival, according to a study in mice led by scientists at the UCLA Jonsson Comprehensive Cancer Center.
The research, published today in the journal Leukemia, could aid in the development of targeted therapies for cancers that have high levels of the RNA-binding protein IGF2BP3 especially acute lymphoblastic and myeloid leukemias that are characterized by chromosomal rearrangements in the mixed lineage leukemia (MLL) gene.
Removing RNA-binding protein in subtype of leukemia can help to slow the cancer s development
Removing a protein that is often overexpressed in a rare and aggressive subtype of leukemia can help to slow the cancer s development and significantly increase the likelihood of survival, according to a study in mice led by scientists at the UCLA Jonsson Comprehensive Cancer Center.
The research, published in the journal Leukemia, could aid in the development of targeted therapies for cancers that have high levels of the RNA-binding protein IGF2BP3 -; especially acute lymphoblastic and myeloid leukemias that are characterized by chromosomal rearrangements in the mixed lineage leukemia (MLL) gene.
Eliminating RNA-binding protein improves survival in aggressive leukemia scienceblog.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scienceblog.com Daily Mail and Mail on Sunday newspapers.